A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFR.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2015
At a glance
- Drugs Bevacizumab (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Oct 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 20 Dec 2011 New trial record